Nataly V. Uboha
Affiliations: | Yale University, New Haven, CT |
Area:
Molecular PsychiatryGoogle:
"Nataly Uboha"Mean distance: 14.13 (cluster 6) | S | N | B | C | P |
Cross-listing: PsychTree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs |
| Dhakras P, Uboha N, Horner V, et al. (2020) Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma Translational Gastroenterology and Hepatology. 5: 55-55 |
| Uboha NV, Eickhoff JC, Chandrasekharan C, et al. (2020) Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461 |
| Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615 |
| Kratz JD, Gillette A, Rehman S, et al. (2020) Defining population response of patient-derived colorectal cancer organoids against prospective clinical outcomes. Journal of Clinical Oncology. 38: 177-177 |
| Goyal L, Lamarca A, Strickler JH, et al. (2020) The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal of Clinical Oncology. 38: e16686-e16686 |
| Kratz JD, LoConte NK, Lubner SJ, et al. (2020) Efficacy of single-agent epidermal growth factor receptor inhibition in the second-line setting for metastatic colorectal cancer with a goal towards retreatment strategies. Journal of Clinical Oncology. 38: e16035-e16035 |
| Boni V, Burris III HA, Liu JF, et al. (2020) CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). Journal of Clinical Oncology. 38: 526-526 |
| Deming DA, Emmerich P, Turk AA, et al. (2020) Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046 |
| Emmerich P, Matkowskyj KA, McGregor S, et al. (2020) VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments. Journal of Clinical Oncology. 38: 3127-3127 |